MedTrace Logo

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

NCT07128381 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-05

No results posted yet for this study

Summary

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML.
* To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

Conditions

  • Myelofibrosis (MF)
  • Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG

Axatilimab (SNDX-6352)

Taken orally

DRUG

Ruxolitinib

Taken orally

Sponsors & Collaborators

  • Incyte, Inc

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Naveen Pemmaraju, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-02
Primary Completion
2031-07-31
Completion
2033-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128381 on ClinicalTrials.gov